Inhaled corticosteroid therapy for patients with persistent asthma: learnings from studies of inhaled budesonide
BE Chipps - Allergy and asthma proceedings, 2009 - ingentaconnect.com
Inhaled corticosteroids (ICSs) are recommended for patients with asthma who use a short-
acting 2-adrenergic agonist more than twice weekly—a key indicator of disease …
acting 2-adrenergic agonist more than twice weekly—a key indicator of disease …
Inhaled corticosteroid therapy for patients with persistent asthma: learnings from studies of inhaled budesonide
BE Chipps - Allergy and asthma proceedings, 2009 - pubmed.ncbi.nlm.nih.gov
Inhaled corticosteroids (ICSs) are recommended for patients with asthma who use a short-
acting beta (2)-adrenergic agonist more than twice weekly--a key indicator of disease …
acting beta (2)-adrenergic agonist more than twice weekly--a key indicator of disease …
[PDF][PDF] Inhaled corticosteroid therapy for patients with persistent asthma: Learnings from studies of inhaled budesonide
BE Chipps - Allergy Asthma Proc, 2009 - scholar.archive.org
Inhaled corticosteroids (ICSs) are recommended for patients with asthma who use a short-
acting 2-adrenergic agonist more than twice weekly—a key indicator of disease persistency …
acting 2-adrenergic agonist more than twice weekly—a key indicator of disease persistency …
[PDF][PDF] Inhaled corticosteroid therapy for patients with persistent asthma: Learnings from studies of inhaled budesonide
BE Chipps - Allergy Asthma Proc, 2009 - researchgate.net
Inhaled corticosteroids (ICSs) are recommended for patients with asthma who use a short-
acting 2-adrenergic agonist more than twice weekly—a key indicator of disease persistency …
acting 2-adrenergic agonist more than twice weekly—a key indicator of disease persistency …
[PDF][PDF] Inhaled corticosteroid therapy for patients with persistent asthma: Learnings from studies of inhaled budesonide
BE Chipps - Allergy Asthma Proc, 2009 - capitalallergy.com
Inhaled corticosteroids (ICSs) are recommended for patients with asthma who use a short-
acting 2-adrenergic agonist more than twice weekly—a key indicator of disease persistency …
acting 2-adrenergic agonist more than twice weekly—a key indicator of disease persistency …
Inhaled corticosteroid therapy for patients with persistent asthma: Learnings from studies of inhaled budesonide.
BE Chipps - Allergy & Asthma Proceedings, 2009 - search.ebscohost.com
Inhaled corticosteroids (ICSs) are recommended for patients with asthma who use a short-
acting β< sub> 2-adrenergic agonist more than twice weekly—a key indicator of disease …
acting β< sub> 2-adrenergic agonist more than twice weekly—a key indicator of disease …
Inhaled corticosteroid therapy for patients with persistent asthma: learnings from studies of inhaled budesonide.
BE Chipps - Allergy and Asthma Proceedings, 2009 - europepmc.org
Inhaled corticosteroids (ICSs) are recommended for patients with asthma who use a short-
acting beta (2)-adrenergic agonist more than twice weekly--a key indicator of disease …
acting beta (2)-adrenergic agonist more than twice weekly--a key indicator of disease …
Inhaled corticosteroid therapy for patients with persistent asthma: Learnings from studies of inhaled budesonide
BE Chipps - Allergy and Asthma Proceedings, 2009 - search.proquest.com
Inhaled corticosteroids (ICSs) are recommended for patients with asthma who use a short-
acting β 2-adrenergic agonist more than twice weekly--a key indicator of disease …
acting β 2-adrenergic agonist more than twice weekly--a key indicator of disease …
[PDF][PDF] Inhaled corticosteroid therapy for patients with persistent asthma: Learnings from studies of inhaled budesonide
BE Chipps - Allergy Asthma Proc, 2009 - capitalallergy.com
Inhaled corticosteroids (ICSs) are recommended for patients with asthma who use a short-
acting 2-adrenergic agonist more than twice weekly—a key indicator of disease persistency …
acting 2-adrenergic agonist more than twice weekly—a key indicator of disease persistency …